Biotech Startups

Nurix Therapeutics develops targeted protein degradation medicines, including degrader-antibody conjugates (DACs), designed to eliminate disease-causing proteins using the cell's natural degradation machinery. It uses a DEL-AI drug discovery engine to advance a multi-modal clinical pipeline targeting diseases in oncology, immunology, and neurology.

5 investors

Nuvig Therapeutics develops immune-modulating medicines for autoimmune diseases by harnessing endogenous regulatory mechanisms to resolve immune dysregulation. The company targets patients with chronic inflammatory and autoimmune conditions.

5 investors

Olio Labs develops drug combination therapies using machine learning to identify treatments that target multiple interacting proteins simultaneously, with initial candidates focused on obesity treatment. The company aims to create pharmaceutical solutions that achieve greater efficacy and lower side effect profiles than existing single-target medications.

5 investors

On Target Laboratories is a company of scientists and researchers focused on cancer surgery, developing products to support surgical oncology. It operates in the biotech and medtech space.

5 investors

OneSkin develops topical skincare products built around OS-01, a proprietary peptide the company says reduces cellular senescence in skin to address visible signs of aging such as wrinkles and hyperpigmentation. It sells science-backed anti-aging skincare directly to consumers, supported by its own peptide and skin-health research.

5 investors

ONI develops the Nanoimager, an automated super-resolution imaging system. The company serves researchers and laboratories in life sciences and microscopy applications.

5 investors

ORIC Pharmaceuticals is a clinical-stage oncology company developing therapies aimed at overcoming cancer treatment resistance, including innate, acquired, and bypass resistance. Its pipeline includes rinzimetostat (ORIC-944) in Phase 1b for prostate cancer and enozertinib (ORIC-114) in Phase 1b for non-small cell lung cancer with EGFR mutations.

5 investors

Orionis Biosciences discovers and engineers molecules that connect proteins on or within cells to reprogram disease-driving processes or activate immune responses. It develops therapeutics for cancer, autoimmune diseases, and neurodegenerative disorders through collaborations with industry and academic institutions.

5 investors

Orum is a global biopharmaceutical company developing cancer therapies that combine protein degraders with antibodies. It focuses on Degrader Antibody Conjugate (DAC) technology to research and develop new therapeutics.

5 investors

Overt Bio develops cell therapies that link genes to immune functions using genome-scale discovery platforms. The company builds programmable immunotherapies targeting cancer patients.

5 investors

Overture develops automation and technology to improve fertility treatment, aiming to lower costs and increase success rates. It targets the fertility care market and the people undergoing such treatment.

5 investors

PanTera develops actinium-225, a therapeutic radioisotope used in precision cancer treatment through radiotheranostics, serving oncology patients and pharmaceutical companies globally. The company operates a production facility in Belgium producing high-purity actinium-225 as an active pharmaceutical ingredient for personalized nuclear medicine treatments.

5 investors

5 investors

Peptone develops a product engine to design small-molecule drug candidates targeting intrinsically disordered proteins, which have been difficult to address with conventional drug discovery approaches.

5 investors

Perseus Proteomics (PPMX) is a Japanese biotech company that uses proprietary antibody technology to develop new antibody-based drugs. It also provides antibody research support services and sells antibodies and reagents, including PTX3 measurement kits.

5 investors

A precision oncology company providing genomic testing and resources to support cancer care decisions, operating under Labcorp Oncology.

5 investors

Phenomic AI is a biotech company developing therapies for solid tumors using a machine-learning-powered transcriptomics platform that analyzes single-cell RNA data to identify drug targets and understand tumor biology. The company develops antibody-based therapies informed by its analysis of cell-cell interactions in tumor microenvironments, with current programs targeting stromal and immune components of difficult-to-treat cancers.

5 investors

Piramidal bridges in-vivo and in-silico intelligence for neuroscience research and clinical applications. The company develops technology that integrates biological data with computational intelligence.

5 investors

Planetary operates a full-stack microbial fermentation platform, building, owning, and running a global network of fermentation facilities to produce bio-based food ingredients and materials at scale for partner companies. Its proprietary BioBlocks fermentation and AI platform is used to scale up, optimize, and manufacture products such as mycoprotein for applications ranging from food to textiles.

5 investors

Pluton is developing a sun-powered, soil-surface biological nutrient system that uses photosynthetic microbial consortia to fix atmospheric nitrogen, improve phosphorus availability, and add carbon to soil for crop growers. Its products are in development and designed to integrate with existing fertilizer and biological input programs in modern agriculture.

5 investors

Postera uses artificial intelligence and computational chemistry to accelerate drug discovery for pharmaceutical companies. The platform combines machine learning, medicinal chemistry, and software engineering to improve the drug development process.

5 investors

Pow.Bio develops a high-efficiency continuous fermentation platform for biomanufacturing that enables production of biotech products at lower cost and faster timelines. The platform serves bioproduct manufacturers across synthetic biology, food, pharmaceuticals, and specialty chemicals.

5 investors

PredxBio analyzes spatial multi-omic tissue data to identify response-defining biology, offering a decision-intelligence platform called SpaceIQ that supports drug development from discovery through clinical trials. It serves biopharma teams with biomarker strategy, patient stratification, and trial optimization insights.

5 investors

Pretzel Therapeutics develops therapeutics targeting bioenergetic dysfunction and mitochondrial disease by addressing defects in mitochondrial DNA function and gene expression. The company leverages expertise in mitochondrial biology and drug discovery to create treatments for diseases associated with mitochondrial dysregulation.

5 investors